



FOR IMMEDIATE RELEASE

August 26, 2019

Contact: Charlie Patterson, charlie@sqcomms.com

Jacqueline Clark, jacqueline@sqcomms.com

George Hodgin, CEO of Biopharmaceutical Research Company, Praises DEA Decision to Process Applications to Grow Cannabis for Research

MONTEREY, CA - George Hodgin, CEO of Biopharmaceutical Research Company (BRC), has issued the following statement lauding the Drug Enforcement Administration's (DEA) announcement that it will begin processing applications to cultivate cannabis for research purposes:

"The DEA's announcement that it will process applications to cultivate cannabis for research use is great news for scientists, health care providers, patients, and regulatory authorities. I started BRC with a dream of helping my fellow veterans use cannabis to treat their wartime wounds. The processing of these applications brings BRC one step closer to helping my fellow veterans find relief for their chronic pain, anxiety, depression, post-traumatic stress and other illnesses. The entire BRC team stands ready to work with the DEA throughout this process, and we are eager to get to work."

About Biopharmaceutical Research Company

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world.

George Hodgin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL Officer and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC's work, visit <https://www.biopharmaresearchco.com/>.

###